December 1, 2022

SILO PROFILE

 

OUR NEW PROFILE IS:  (NASDAQ: SILO)

  • Recently SILO announced its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method
  • Recently SILO announced its topically administered Ketamine reached a positive end point in an animal study.
  • SILO uplisted to Nasdaq on September 27 and completed a $5.7 million public offering 
  • SILO has $8.7 million in the treasury and is virtually debt free according to their 10Q filed on August 1 
  • SILO entered into A sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease;
  • SILO entered into A scientific research agreement with the University of California San Francisco (UCSF) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; 
  • SILO signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) to explore a patent focused on enhanced targeting of therapeutic agents to the central nervous system; 
  • SILO signed a second exclusive option agreement with UMB to license a joint-homing peptide targeted at arthritis-inflamed joints
  • SILO entered into an agreement with Columbia University granting it an option to license two distinct assets currently under development, one focused on Alzheimer’s disease and a second focused on PTSD and stress.

Check out the Company website here:   silopharma.com

*****BREAKING NEWS RELEASED MINUTES AGO*****

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

Dosing study of SPC-14 demonstrates efficacy for increasing memory function

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease (AD), as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York.

SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer’s disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.

“The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer’s,” said Eric Weisblum Chief Executive Officer of Silo Pharma. “SPC-14 is a therapeutic that utilizes ketamine as one part of the formulation. With safety data already available from the approved therapeutic in the compound, we believe SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway. This will allow Silo Pharma to reach efficacy clinical trials faster and save costs in potentially bringing to market a potential novel new treatment for Alzheimer’s patients.

“On-going research studies are currently being conducted by Silo and we look forward to sharing these results as additional data becomes available,” Weisblum added.

Silo Pharma’s Commercial Evaluation License Agreement (CELA) with Columbia University grants an option to license two distinct assets currently under development: SPC-14 targeting Alzheimer’s disease and SPC-15 targeting stress-induced affective disorders.

_______________________

Hello Everyone,

The market is set top open shortly and we have something that we want you to put back on your radar.

Our recent profiles have been on fire.

Last Thursday our profile opened at .197.

Two sessions later it hit .28 and the next session it hit .29 for over 40% in real gains.  Congrats.

The profile before that gapped up from $1.86 and opened at $2.69. It just hit $5.25 for a potential 95% gain if you maxed out.

Turn your attention to SILO right away for today’s session. 

Silo Pharma Inc (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. 

Intellectual property: To date, Silo has filed 4 provisional patent applications related to the use of the central nervous system-homing peptides covered by the UMB Option Agreement to deliver certain compounds, including a nonsteroidal anti-inflammatory drug and/or psilocybin, for the treatment of arthritis, central nervous system diseases, neuroinflammatory diseases as well as cancer. In addition, pursuant to the Company’s acquisition of NFID, Silo acquired three trademarks related to the NFID brand. 

SILO is Harnessing the Power of Psychedelics to Deliver Breakthrough Medical Solutions

Silo has entered into research agreements and partnerships with multiple leading medical universities, including: 

  • A sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease; 
  • A scientific research agreement with the University of California San Francisco (UCSF) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation; 
  • An exclusive license agreement with the University of Maryland, Baltimore (UMB) to explore a patent focused on enhanced targeting of therapeutic agents to the central nervous system; 
  • A second exclusive option agreement with UMB to license a joint-homing peptide targeted at arthritis-inflamed joints; and 
  • An agreement with Columbia University granting it an option to license two distinct assets currently under development, one focused on Alzheimer’s disease and a second focused on PTSD and stress. 

Psilocybin is considered a serotonergic hallucinogen and is an active ingredient in some species of mushrooms. Recent industry studies using psychedelics, such as psilocybin, have been promising, and Silo Pharma believes there is a large unmet need with many people suffering from depression, mental health issues and neurological disorders. While classified as a Schedule I substance under the Controlled Substances Act (“CSA”), there is an accumulating body of evidence that psilocybin may have beneficial effects on depression and other mental health conditions. Therefore, the U.S. Food and Drug Administration (“FDA”) and U.S. Drug Enforcement Agency (“DEA”) have permitted the use of psilocybin in clinical studies for the treatment of a range of psychiatric conditions. 

The potential of psilocybin therapy in mental health conditions has been demonstrated in a number of academic-sponsored studies over the last decade. In these early studies, it was observed that psilocybin therapy provided rapid reductions in depression symptoms after a single high dose, with antidepressant effects lasting for up to at least six months for a number of patients. These studies assessed symptoms related to depression and anxiety through a number of widely used and validated scales. The data generated by these studies suggest that psilocybin is generally well-tolerated and has the potential to treat depression when administered with psychological support. 

Silo Pharma has engaged in discussions with a number of world-renowned educational institutions and advisors regarding potential opportunities and have formed a scientific advisory board that is intended to help advise management regarding potential acquisition and development of products. 

In addition, as more fully described below, Silo Pharma has entered into a license agreement with the University of Baltimore, Maryland, and has entered into a joint venture with Zylo Therapeutics, Inc., with respect to certain intellectual property and technology that may be used for targeted delivery of potential novel treatments. In addition, Silo Pharma has recently entered into a sponsored research agreement with Columbia University pursuant to which it has been granted an option to license certain patents and inventions relating to the treatment of Alzheimer’s disease and stress-induced affective disorders using Ketamine in combination with certain other compounds. 

Silo Pharma plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand our business to focus on this new line of business. 

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with  Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.

SILO Pipeline:

Silo Pharma believes in following the science to identify the best application for a therapeutic rather by targeting indications with the biggest need and selecting the best route of delivery for patients. Our current assets have shown promise in a range of illnesses and diseases, including Alzheimer’s; Parkinson’s; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

SILO Pharma’s Primary Asset Has Extraordinary Potential

SPC-14 Targeting Alzheimer’s 

505(b)(2) Pathway / preclinical testing and proof-of-concept being lead by inventor Dr. Christine Denny of Columbia University / SPC-14 has shown reduced hyponeophagia in animal studies / SPC-14 may reduce behavioral despair / Silo has licensed technology with Columbia and has recently entered into a scientific research agreement with Dr. Denny’s lab 

Market Opportunity – Alzheimer’s Disease / 6.5 million Americans suffer from Alzheimer’s and related diseases /  ~1 in 9 Americans 65+ have Alzheimer’s v U.S. market for relevant drugs expected to reach $5 billion by 2027 

Technology – Licensed from Columbia University / SPC-14 is a novel drug combining two approved therapeutics / SPC-14 targets NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimers.

SPC-15 Targeted prophylactic treatment—Stress-induced affective disorders  

Sponsored Research Agreement with Columbia University Prevention of stress-induced affective disorders / Increasing stress resilience in military, first responders, and other populations at high risk of PTSD / Predicting the level of severity or progression such disorders / Molecular targets for use in drug discovery of innovative treatments. 

Market Opportunity – Targeted prophylactic treatment—Stress-induced affective disorders / 26% of Americans 18+ suffer from anxiety, PTSD and other disorders / This number has escalated post-COVID-19 / U.S. market for relevant drugs expected to reach $13 billion by 2027 

Technology – Metabolomic biomarkers predict response to pharmacological treatments / Utilizes ketamine compositions as a method for treatment and prevention.

SP-26 Time-Released Psilocybin, Ketamine 

Deliver Ketamine or Psilocybin in a time-released manner / Will time-release diminish the hallucinogenic effects of these psychedelics / Pre clinical study underway shows Z-pod can hold and distribute Ketamine / Efficacy study in animals underway. 

Market Opportunity – Time-Released Psilocybin, Ketamine / Multiple Indications 

Technology – Joint Venture with Zylö Therapeutics, Inc. / Clinical development of psilocybin using ZTI’s Z-pod technology / Clinical development of Zylo’s sustained release topical delivery system.

SPU-16 CNS Homing Peptide 

May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord / May be used for diagnosing and monitoring MS / Decreases toxicity of existing therapeutics / Animal study results show much improved delivery of therapeutics and decreased toxicity. 

Market Opportunity – Multiple Sclerosis (MS) / There are approximately 400,000 Americans and 2.5 million people worldwide with MS / The most widespread disabling neurological condition of young adults / Global market for MS drugs expected to reach $25.3 billion by 202 

Technology- Licensed from University of Maryland Baltimore / Patent issued / Central nervous system-homing peptides / Use for investigation and treatment of MS and other neuroinflammatory pathology.

SPU-21 Arthritogenic Joint Homing Peptides Utilizing Psilocybin  

Identify markers of arthritic inflammation in joints / Isolate phage clones that preferentially target inflamed joints of arthritic Lewis rats / Peptide significantly inhibited arthritic progression in this animal model / Further studies are underway at UMB. 

Market Opportunity – Rheumatoid Arthritis (RA) / 1.3M U.S. adults suffer from RA / The most common autoimmune disease in U.S. / U.S. market for RA drugs expected to reach $63 billion by 2027 

Technology- Development plan to utilizing liposomal Homing Peptide to deliver targeted psilocybin / The ability of the peptides to target inflamed epithelium suggest they could be used to target drug delivery. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides can be used to treat autoimmune diseases, including but not limited to RA. 

In July SILO announced its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method.  In previous work, ART-1-Cy7-liposomes injected i.v. demonstrated homing to arthritic joints and 4 hours was an optimal time point for high fluorescence intensity in the hind paws. The results of this new study show that the time kinetics and quantitative aspects of liposomes administered subcutaneous were not much different from that of liposomes injected i.v. In fact, despite some initial delay, the signal strength showed a trend towards a higher level in subcutaneous than in i.v. 

Eric Weisblum, CEO of Silo Pharma commented “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic agents. We suggest that this drug delivery approach would not only enhance efficacy but also reduce systemic toxicity.” 

Also, in July SILO announced its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.  

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.” 

How SILO Pharma’s Drug Delivery Platform Could Cause Massive Changes to How Diseases Are Treated 

Research has clearly shown that psychedelics – such as psilocybin – can offer significant benefits to those suffering from a number of disorders. But to date, the issue has been developing a psychedelic-based solution for these sufferers that was both practical and effective. Thanks to the potential of SILO Pharma’s unique drug delivery platform – developed in conjunction with university research – we could be on the verge of a significant breakthrough in treatment. SILO Pharma’s assets and research could be transformative to the well-being of patients worldwide…and disruptive to the healthcare industry as a whole. That alone sets Silo Pharma (OTC: SILO) apart from others in both the psychedelic and biopharma arenas. 

The research and development – based on the company’s unique homing peptide – could not only prove to be effective in the delivery of psychedelics…but also in delivery of traditional medication. That type of potential is deserving of attention from investors…but it’s also more difficult to project. A potential comparable stock that has demonstrated the potential for this company’s upside, however, does exist in the cannabis space. 

1) Double Play Investment Opportunity – Unlike many companies generating attention in the psychedelic space, SILO Pharma is focused on developing potential breakthroughs by combining traditional therapeutics with the power of psychedelic research.

2) Rapidly Growing Market – The market for psychedelics is projected to grow at a CAGR of 16.3% between now and 2027, when it is expected to reach $6.8 billion.

3) Potential Game-Changing Drug Delivery Platform – SILO Pharma’s potentially game-changing drug delivery platform may be used to treat a number of devastating diseases, including Rheumatoid Arthritis and Multiple Sclerosis and is likely to generate considerable attention from larger companies, making for attractive buyout potential.

4) Following a Proven Blueprint for Success – The company is following the same path forged in the cannabis sector by GW Pharma, and is working to combine the powerful healing benefits of psilocybin with its own unique drug delivery system in the hopes of developing a true game-changer that could ultimately prove disruptive to the entire healthcare industry.

5) Proven Leadership Team – Silo Pharma is led by an experienced team of business builders and researchers poised to make the company’s dream a reality. This team includes CEO Eric Weisblum, with over 20 years investing, building and managing businesses as well as an impressive scientific advisory board.

SILO

  • GlobeNewswireyesterday

    Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

    Silo and Columbia University continue research on SPC-14 for Alzheimer’s and SPC-15 for Stress Induced DisordersENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced it has entered into an agreement with Columbia University pursuant to which Silo has been granted an extension for its option to license certain as

  • GlobeNewswire9 days ago

    Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

    Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated a

  • GlobeNewswire13 days ago

    Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

    Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference bein

  • GlobeNewswire16 days ago

    Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

    Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working with Premier Consulting as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting re

  • GlobeNewswire19 days ago

    Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

    ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, at a public offering price of $5.00 per share. Silo Ph

  • GlobeNewswire22 days ago

    Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

    Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO”ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds

  • GlobeNewswirelast month

    Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

    ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it will effect a 1-for-50 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The reverse stock split will become effective at the open of business on Thursday, Se

  • GlobeNewswire3 months ago

    Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

    Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesi

  • GlobeNewswire3 months ago

    Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

    ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. Eric Weisblum, CEO of Silo Pharma commented “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of a

  • GlobeNewswire4 months ago

    Silo Pharma Expands License Agreement and Patent Portfolio

    Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of traditional and psychedelics as a therapeutic, today announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (

  • GlobeNewswire5 months ago

    Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

    Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it in conjunction with the University of California San Francisco (UCSF), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of this study, the researchers are collecting blood samples to

  • GlobeNewswire5 months ago

    IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.

    LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operatin

  • GlobeNewswire6 months ago

    Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

    SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies.ENGLEWOOD CLIFFS, N.J., April 20, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it has produced its first batch of Liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization).Eric Weisblum, CEO of Silo Pharma state

  • GlobeNewswire7 months ago

    Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

    IND Enabling Study to prepare Silo Pharma Homing Peptides for ClinicENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it has entered into an agreement with Frontage Laboratories, a CRO (contract research organization), providing integrated, science-driven, product development services throughout the drug discovery and development proces

  • GlobeNewswire7 months ago

    IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

    NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announces it has selected the corporate communications expertise of IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities. Silo is committed to developing innovative solutions to address conditions such as post-traumatic

  • GlobeNewswire8 months ago

    Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

    Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as Joint-homing peptides. These peptides are being developed for use in the investigation and treatme

  • GlobeNewswire10 months ago

    Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

    Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC (“Donohoe”) for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market. Silo Pharma hopes to gain additional exposure and access to a wider base of retail and institutional investor

  • GlobeNewswire11 months ago

SILO EXECUTIVE TEAM

Silo Pharma’s is Led by an Experienced Management Team and an Impressive Group of Scientific Advisors

CEO Eric Weisblum has over 20 years investing, building and managing businesses and will lead a scientific advisory board of reputable medical professionals to work and guide the company through the different stages of research, licensing, partnerships and trials.

Prior, Mr. Weisblum was President of Sableridge Capital for five years. Eric currently serves on the board of directors of Aikido Pharma., a Nasdaq listed biotech company focused on the commercialization of oncology therapeutics. In addition to being an active investor in both public and private companies, Mr. Weisblum has provided managerial assistance and guidance to help companies execute on their business strategy.

 

Director Wayne Linsley has been an entrepreneur for over 40 years. In 1979, he received a Bachelor’s Degree in Business Administration from Sienna College in Loudonville, New York.

He has since been involved with real estate brokerage and residential development, construction, finance, telecommunications. Since 2009 he has worked for and is currently a Vice President for CFO Oncall, Inc., a financial reporting firm that works with publicly traded companies.

 

Director Kevin Munoz, MD, currently serves as Director of Operations at Physical Medicine and Rehabilitation where he has responsibility for the day-to-day management of all office operations with a focus on ensuring and increasing patient satisfaction. Prior to that, he led the configuration efforts during an enterprise-wide implementation of application software that also included streamlining and improving business processes.

Sincerely,

DISCLAIMER

*****We have been compensated for this email.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  WE HAVE BEEN COMPENSATED A FEE OF EIGHTEEN THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA, LLC FOR A ONE DAY SILO AWARENESS CAMPAIGN.  WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA, LLC FOR A ONE DAY SILO AWARENESS CAMPAIGN.  NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: O22 LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.  RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD O22, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND O22, LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD O22, LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.O22, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. O22, LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, ANDO22, LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.  IN PREPARING THIS PUBLICATION,O22, LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22, LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, O22, LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. O22, LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS O22, LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. 022, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.